These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 33814541)

  • 1. Impact of a Bayesian Individualization of Cyclosporine Dosage Regimen for Children Undergoing Allogeneic Hematopoietic Cell Transplantation: A Cost-Effectiveness Analysis.
    Beyron C; Ceraulo A; Bertrand Y; Bleyzac N; Philippe M
    Ther Drug Monit; 2021 Aug; 43(4):481-489. PubMed ID: 33814541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of pharmacokinetic models in paediatric onco-haematology: effects on clinical outcome through the examples of busulfan and cyclosporine.
    Bleyzac N
    Fundam Clin Pharmacol; 2008 Dec; 22(6):605-8. PubMed ID: 19049662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation.
    Li TF; Hu L; Ma XL; Huang L; Liu XM; Luo XX; Feng WY; Wu CF
    Acta Pharmacol Sin; 2019 Dec; 40(12):1603-1610. PubMed ID: 31341257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of continuous and twice-daily infusions of cyclosporine A for graft-versus-host-disease prophylaxis in pediatric hematopoietic stem cell transplantation.
    Umeda K; Adachi S; Tanaka S; Ogawa A; Hatakeyama N; Kudo K; Sakata N; Igarashi S; Ohshima K; Hyakuna N; Chin M; Goto H; Takahashi Y; Azuma E; Koh K; Sawada A; Kato K; Inoue M; Atsuta Y; Takami A; Murata M;
    Pediatr Blood Cancer; 2015 Feb; 62(2):291-298. PubMed ID: 25307105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing cyclosporine A dose post allogeneic hematopoietic stem cell transplantation in paediatric cancer patients.
    Elnaggar M; Hafez H; Abdallah A; Hamza M; Khalaf MM; El-Haddad A
    J Oncol Pharm Pract; 2024 Sep; 30(6):983-991. PubMed ID: 37528663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian Networks: A New Approach to Predict Therapeutic Range Achievement of Initial Cyclosporine Blood Concentration After Pediatric Hematopoietic Stem Cell Transplantation.
    Leclerc V; Ducher M; Bleyzac N
    Drugs R D; 2018 Mar; 18(1):67-75. PubMed ID: 29404858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral cyclosporine A treatment is feasible after myeloablative conditioning in allogeneic hematopoietic stem cell transplantation.
    Nygaard M; Hovgaard D; Schjødt IM; Andersen NS; Vindeløv L; Sengeløv H
    J Clin Pharm Ther; 2015 Jun; 40(3):358-61. PubMed ID: 25829023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Goal-Oriented Monitoring of Cyclosporine Is Effective for Graft-versus-Host Disease Prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia Major.
    Gauthier A; Bleyzac N; Garnier N; Kebaili K; Joly P; Goutagny MP; Mollet I; Goutelle S; Renard C; Bertrand Y
    Biol Blood Marrow Transplant; 2020 Dec; 26(12):2285-2291. PubMed ID: 32007639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis.
    Punnett A; Sung L; Price V; Das P; Diezi M; Doyle J; Dupuis LL
    Ther Drug Monit; 2007 Dec; 29(6):750-7. PubMed ID: 18043472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine levels > 195 μg/L on day 10 post-transplant was associated with significantly reduced acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Bianchi M; Heim D; Lengerke C; Halter J; Gerull S; Kleber M; Tsakiris DA; Passweg J; Tzankov A; Medinger M
    Ann Hematol; 2019 Apr; 98(4):971-977. PubMed ID: 30542943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of cyclosporine A in pediatric patients with thalassemia undergoing allogeneic hematopoietic stem cell transplantation.
    Cai R; Zhang L; Wu T; Huang Y; Lu J; Huang T; Wu Y; Wu D; Qi J; Niu L; Xiao Y; Chen X; Liu Y; Luo Y; Liu T
    Eur J Clin Pharmacol; 2024 May; 80(5):685-696. PubMed ID: 38329479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and Bayesian estimation of cyclosporine in a Tunisian population of hematopoietic stem cell transplant recipient.
    Eljebari H; Gaies E; Fradj NB; Jebabli N; Salouage I; Trabelsi S; Lakhal M; Klouz A
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1517-24. PubMed ID: 22527344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
    Stocker N; Duléry R; Battipaglia G; Brissot E; Médiavilla C; Sestili S; Paviglianiti A; Ledraa T; Mohty R; Bazarbachi A; Belhocine R; Vekhoff A; Ruggeri A; Mohty M; Malard F
    Eur J Haematol; 2019 Jul; 103(1):10-17. PubMed ID: 30958904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of cyclosporine-A concentration in T-cell replete haploidentical allogeneic stem cell transplantation.
    Yang X; Yang S; Sun A; Qiu H; Tang X; Han Y; Wu D
    Clin Transplant; 2018 Apr; 32(4):e13220. PubMed ID: 29493007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial dosage optimisation of cyclosporine in Chinese paediatric patients undergoing allogeneic haematopoietic stem cell transplantation based on population pharmacokinetics: a retrospective study.
    Feng H; Wang X; Zheng W; Liu S; Jiang H; Lin Y; Qiu H; Chan TF; Huang M; Li Y; Mo X; Li J
    BMJ Paediatr Open; 2023 Aug; 7(1):. PubMed ID: 37643815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Premature cyclosporine cessation and TBI-containing conditioning regimen increase the risk of acute GvHD in children undergoing unrelated donor hematopoietic stem cell transplantation.
    Szmit Z; Kałwak K; Król A; Mielcarek-Siedziuk M; Salamonowicz M; Frączkiewicz J; Ussowicz M; Owoc-Lempach J; Gorczyńska E
    Adv Clin Exp Med; 2019 Sep; 28(9):1185-1192. PubMed ID: 31430073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients.
    Woillard JB; Lebreton V; Neely M; Turlure P; Girault S; Debord J; Marquet P; Saint-Marcoux F
    Br J Clin Pharmacol; 2014 Oct; 78(4):836-46. PubMed ID: 24698009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of cyclosporine in hematopoietic stem cell transplant patients: consideration of genetic polymorphisms.
    Kim MG; Kim IW; Choi B; Han N; Yun HY; Park S; Oh JM
    Ann Pharmacother; 2015 Jun; 49(6):622-30. PubMed ID: 25818517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.